Dr. William Kevin Kelly DO Medical Oncologist

Dr. William Kelly is a medical oncologist in Philadelphia, Pennsylvania and is affiliated with multiple hospitals in the area, including Lankenau Medical Center and Thomas Jefferson University Hospital. He received his medical degree from Philadelphia College of Osteopathic Medicine and has been in practice for 28 years. Dr. Kelly accepts several types of health insurance, listed below. He is one of 15 doctors at Lankenau Medical Center and one of 19 at Thomas Jefferson University Hospital who specialize in Medical Oncology.

Are you Dr. Kelly? Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: General Oncology

Hospital Affiliation

Thomas Jefferson University Hospital
Ranked #27 in Cancer

Lankenau Medical Center
High performing in Cancer

Education & Medical Training

Memorial Sloan-Kettering Cancer Center
Fellowship, Medical Oncology, 1990–1993

Philadelphia College of Osteopathic Medicine
Class of 1986

Certifications & Licensure

American Board of Internal Medicine
Certified 23 years in Internal Medicine

American Board of Internal Medicine
Certified 21 years in Medical Oncology

NY State Medical License
Active through 2015

Awards, Honors & Recognition

Meaningful Use Stage 1 Certification, Centers for Medicare & Medicaid Services

Super Doctor, SuperDoctors.com

Publications & Presentations

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
Smith, M. R.,Halabi, S.,Ryan, C. J.,Hussain, A.,Vogelzang, N.,Stadler, W.,Hauke, R. J.,Monk, J. P.,Saylor, P.,Bhoopalam, N.,Saad, F.,Sanford, B.,Kelly, W. K.,Morris, M.,Small, E. J.

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: Results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
Aggarwal, R.,Halabi, S.,Kelly, W. K.,George, D.,Mahoney, J. F.,Millard, F.,Stadler, W. M.,Morris, M. J.,Kantoff, P.,Monk, J. P.,Carducci, M.,Small, E. J.

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
Gibney, G. T.,Aziz, S. A.,Camp, R. L.,Conrad, P.,Schwartz, B. E.,Chen, C. R.,Kelly, W. K.,Kluger, H. M.

See all 21 publications

Insurances Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • AmeriHealth Direct POS
  • Amerihealth HMO
  • AmeriHealth PPO
  • BCBS Blue Card PPO
  • CIGNA Open Access
  • First Health PPO
  • Great West PPO
  • HealthAmerica HealthAssurance PPO
  • Horizon BCBS Direct Access
  • Horizon BCBS HMO
  • Horizon BCBS POS
  • Horizon BCBS PPO
  • Humana ChoiceCare Network PPO
  • IBC Keystone HMO / POS
  • IBC Personal Choice PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • QualCare HMO
  • QualCare PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Report a Correction — If you are aware of information on this page that is out of date or incorrect, please let us know.

Patient Advice & Support

See More
Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Nearby Medical Oncologists

See all Medical Oncologists near Philadelphia, PA See all Medical Oncologists in Pennsylvania

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.